Clinical Trial Detail

NCT ID NCT04104893
Title A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation (CHOMP)
Recruitment Recruiting
Gender male
Phase Phase II
Variant Requirements Yes
Sponsors VA Office of Research and Development
Indications

prostate adenocarcinoma

prostate small cell carcinoma

Therapies

Pembrolizumab

Age Groups: adult senior

Additional content available in CKB BOOST